These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30315192)

  • 21. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China.
    Wang Z; Zhang M; Zhang R; Liu L; Shen Y; Wang J; Lu H
    BMC Infect Dis; 2019 Apr; 19(1):313. PubMed ID: 30961560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil.
    Cerqueira DM; Amorim RM; Silva RR; Camara GN; Brígido MM; Martins CR
    Mem Inst Oswaldo Cruz; 2004 Dec; 99(8):877-82. PubMed ID: 15761606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of transmitted antiretroviral drug resistance in treatment-naive HIV-1-infected persons in a large South Central United States clinic.
    Kleyn TJ; Liedtke MD; Harrison DL; Lockhart SM; Salvaggio MR; Ripley TL; Rathbun RC
    Ann Pharmacother; 2014 Apr; 48(4):470-5. PubMed ID: 24473489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 subtypes and primary antiretroviral resistance mutations in antiretroviral therapy naive HIV-1 infected individuals in Turkey.
    Sayan M; Willke A; Ozgunes N; Sargın F
    Jpn J Infect Dis; 2013; 66(4):306-11. PubMed ID: 23883841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaoundé, Cameroon.
    Teto G; Tagny CT; Mbanya D; Fonsah JY; Fokam J; Nchindap E; Kenmogne L; Njamnshi AK; Kanmogne GD
    Sci Rep; 2017 Oct; 7(1):14136. PubMed ID: 29074854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
    Cardoso LP; Queiroz BB; Stefani MM
    J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limited evolution but increasing trends of primary non-nucleoside reverse transcriptase inhibitor resistance mutations in therapy-naive HIV-1-infected individuals in India.
    Neogi U; Gupta S; Palchaudhuri R; Rao SD; Shastri S; Diwan V; Laishram RS; De Costa A; Shet A
    Antivir Ther; 2014; 19(8):813-8. PubMed ID: 24699043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic Diversity and Drug Resistance Among Antiretroviral Treatment-Failed Individuals from 2010 to 2012 in Honghe, China.
    Yang C; Yang S; Li J; Yang B; Liu J; Li H; Bian Z
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):822-9. PubMed ID: 25919896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of Antiretroviral Drug Resistance Mutations in HIV Seropositive Patients from an Outpatient Clinic of a Large University Hospital from São Paulo, Brazil.
    Oliveira Constantinov E; Brígido LFM; Fonseca LAM; Casseb J;
    AIDS Res Hum Retroviruses; 2020 Mar; 36(3):200-204. PubMed ID: 31842584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for antiretroviral drug resistance among treatment-naive human immunodeficiency virus type 1-infected individuals in Lebanon.
    Mokhbat JM; Melhem NM; El-Khatib Z; Zalloua P
    J Infect Dev Ctries; 2014 Mar; 8(3):339-48. PubMed ID: 24619266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey.
    Steegen K; Carmona S; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; MacLeod W; Sanne I; Stevens WS
    PLoS One; 2016; 11(12):e0166305. PubMed ID: 27907009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals.
    Vahabpour R; Bokharaei-Salim F; Kalantari S; Garshasbi S; Monavari SH; Esghaei M; Memarnejadian A; Fakhim A; Keyvani H
    Arch Virol; 2017 Jun; 162(6):1477-1485. PubMed ID: 28181034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low HIV-1 transmitted drug resistance in Bulgaria against a background of high clade diversity.
    Alexiev I; Shankar A; Wensing AM; Beshkov D; Elenkov I; Stoycheva M; Nikolova D; Nikolova M; Switzer WM
    J Antimicrob Chemother; 2015; 70(6):1874-80. PubMed ID: 25652746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon.
    Ceccarelli L; Salpini R; Moudourou S; Cento V; Santoro MM; Fokam J; Takou D; Nanfack A; Dori L; Torimiro J; Sarmati L; Andreoni M; Perno CF; Colizzi V; Cappelli G
    J Med Virol; 2012 May; 84(5):721-7. PubMed ID: 22431019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda.
    Weidle PJ; Downing R; Sozi C; Mwebaze R; Rukundo G; Malamba S; Respess R; Hertogs K; Larder B; Ochola D; Mermin J; Samb B; Lackritz E
    AIDS; 2003 Jul; 17 Suppl 3():S39-48. PubMed ID: 14565608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan patients initiating antiretroviral therapy.
    Lihana RW; Khamadi SA; Lubano K; Lwembe R; Kiptoo MK; Lagat N; Kinyua JG; Okoth FA; Songok EM; Makokha EP; Ichimura H
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1211-7. PubMed ID: 19954302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of Nucleoside Reverse Transcriptase Inhibitor-Associated Mutations in the RNase H Region of HIV-1 Subtype C Infected Individuals.
    Ngcapu S; Theys K; Libin P; Marconi VC; Sunpath H; Ndung'u T; Gordon ML
    Viruses; 2017 Nov; 9(11):. PubMed ID: 29117130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct drug resistance profile of HIV-1 subtype A strain circulating in Georgia.
    Dvali N; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Georgian Med News; 2015 Mar; (240):19-24. PubMed ID: 25879553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.
    Aghokeng AF; Kouanfack C; Laurent C; Ebong E; Atem-Tambe A; Butel C; Montavon C; Mpoudi-Ngole E; Delaporte E; Peeters M
    AIDS; 2011 Nov; 25(17):2183-8. PubMed ID: 21860346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.